文献速递肾癌与肾肿瘤

非转移性肾细胞癌伴瘤栓术后复发预测列线图的开发与验证

Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.
PubMed 文献 · J Urol · 2017-04-12

本研究基于5家机构2000至2013年收治的636例非转移性肾细胞癌伴静脉瘤栓患者,利用竞争风险分析筛选独立预测因子并构建复发列线图。列线图预测准确性在开发队列与验证队列相似(AUC 0.726与0.724),且高于UISS、SSIGN和Sorbellini模型。

要点

  • 列线图纳入肿瘤直径、体重指数、术前血红蛋白低于正常下限、瘤栓水平、肾周脂肪侵犯和非透明细胞组织学。
  • 总体估计5年无复发生存率为49%,0、1、2和超过2个危险因素患者分别为77%、53%、47%和20%。
  • 列线图预测准确性高于UISS(AUC 0.726 vs 0.595,p=0.001)、SSIGN(AUC 0.713 vs 0.612,p=0.04)和Sorbellini模型(AUC 0.709 vs 0.638,p=0.02)。

核心结论

  • 作者提出了用于非转移性肾细胞癌伴静脉瘤栓患者术后复发预测的列线图。
  • 作者认为改善个体化术后风险评估可能有助于未来辅助临床试验的更好设计与分析。

研究设计与样本

  • 回顾性收集2000至2013年5家机构收治的非转移性肾细胞癌伴瘤栓患者数据,共636例,包括开发队列465例和验证队列171例。
  • 利用竞争风险分析筛选复发独立预测因子并构建列线图,比较开发队列与验证队列以及列线图与UISS、SSIGN和Sorbellini模型的预测准确性。

主要发现

  • 独立预测因子包括肿瘤直径、体重指数、术前血红蛋白低于正常下限、瘤栓水平、肾周脂肪侵犯和非透明细胞组织学。
  • 总体估计5年无复发生存率为49%。
  • 0、1、2和超过2个危险因素患者的5年无复发生存率分别为77%、53%、47%和20%。
  • 预测准确性在开发队列与验证队列相似(AUC 0.726与0.724)。
  • 列线图预测准确性高于UISS(AUC 0.726 vs 0.595,p=0.001)、SSIGN(AUC 0.713 vs 0.612,p=0.04)和Sorbellini模型(AUC 0.709 vs 0.638,p=0.02)。

关键数值与推荐

  • 列线图包含6个独立预测因子:肿瘤直径、体重指数、术前血红蛋白低于正常下限、瘤栓水平、肾周脂肪侵犯和非透明细胞组织学。
  • 总体估计5年无复发生存率为49%。
  • 0、1、2和超过2个危险因素患者的5年无复发生存率分别为77%、53%、47%和20%。
  • 开发队列与验证队列AUC分别为0.726和0.724。
  • 列线图与UISS、SSIGN、Sorbellini模型比较的p值分别为0.001、0.04和0.02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Following surgery for nonmetastatic renal cell carcinoma with tumor thrombus the risk of recurrence is significant but variable among patients. The purpose of this study was to develop and validate a predictive nomogram for individual estimation of recurrence risk following surgery for renal cell carcinoma with venous tumor thrombus. MATERIALS AND METHODS: Comprehensive data were collected on patients with nonmetastatic renal cell carcinoma and thrombus treated at a total of 5 institutions from 2000 to 2013. Independent predictors of recurrent renal cell carcinoma from a competing risks analysis were developed into a nomogram. Predictive accuracy was compared between the development and validation cohorts, and between the nomogram and the UISS (UCLA Integrated Staging System, SSIGN (Stage, Size, Grade and Necrosis) and Sorbellini models. RESULTS: A total of 636 patients were analyzed, including the development cohort of 465 and the validation cohort of 171. Independent predictors, including tumor diameter, body mass index, preoperative hemoglobin less than the lower limit of normal, thrombus level, perinephric fat invasion and nonclear cell histology, were developed into a nomogram. Estimated 5-year recurrence-free survival was 49% overall. Five-year recurrence-free survival in patients with 0, 1, 2 and more than 2 risk factors was 77%, 53%, 47% and 20%, respectively. Predictive accuracy was similar in the development and validation cohorts (AUC 0.726 and 0.724, respectively). Predictive accuracy of the thrombus nomogram was higher than that of the UISS (AUC 0.726 vs 0.595, p = 0.001), SSIGN (AUC 0.713 vs 0.612, p = 0.04) and Sorbellini models (AUC 0.709 vs 0.638, p = 0.02). CONCLUSIONS: We present a predictive nomogram for postoperative recurrence in patients with nonmetastatic renal cell carcinoma with venous thrombus. Improving individual postoperative risk assessment may allow for better design and analysis of future adjuvant clinical trials.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Abel EJ, Masterson TA, Karam JA, et al. Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol. 2017. PMID: 28411071. doi:10.1016/j.juro.2017.04.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。